AMG133 peptide payload TFA

Product Name: AMG133 peptide payload TFA

Sequence: His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ser-Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Lys(BrAc)-NH2

Purity: 99%

Form: White to off-white Solid

Storage : Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year

Chemical Formula: C196H290BrN55O69.xC2HF3O2 

Molar Mass: 4600.70 (free base)

Application: AMG133 peptide payload TFA is a GLP-1 analog agonist peptide designed for research on incretin signaling, metabolic regulation, and obesity-related pathways. It potently activates the glucagon-like peptide-1 receptor (GLP-1R), supporting studies of appetite control, glucose metabolism, insulinotropic signaling, and body weight regulation. AMG133 peptide payload TFA has been associated with weight loss and metabolic improvement activities, making it valuable for investigating GLP-1R-mediated therapeutic mechanisms. This peptide can also be used as a key payload component for the synthesis of AMG 133, supporting research into next-generation peptide-based metabolic disease interventions.

Current Research: AMG133 peptide payload TFA is a GLP-1 analog agonist peptide used in metabolic disease and incretin signaling research. As a glucagon-like peptide-1 receptor-targeting peptide payload, it is designed to activate GLP-1R-dependent pathways involved in glucose regulation, insulinotropic signaling, appetite control, gastric emptying, and body weight regulation. The TFA salt format is commonly used for synthetic peptide handling and analytical workflows, while the peptide itself is valuable for research into GLP-1 receptor pharmacology and next-generation peptide-based metabolic intervention strategies. GLP-1 receptor signaling is one of the most important pathways in modern metabolic disease research. Native GLP-1 is an incretin hormone released from intestinal L cells after nutrient intake. It enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and acts on central and peripheral circuits involved in appetite regulation. GLP-1 analogs are widely studied because they can reproduce or extend these biological effects in experimental systems. AMG133 peptide payload TFA provides a defined peptide component for investigating how engineered GLP-1-like sequences interact with GLP-1R biology. A major research application of AMG133 peptide payload TFA is GLP-1 receptor activation analysis. Researchers can use the peptide in GLP-1R-expressing cell systems to evaluate receptor engagement and downstream signaling. Common readouts include cAMP accumulation, PKA activation, EPAC pathway activity, calcium signaling, ERK phosphorylation, β-arrestin recruitment, receptor internalization, and transcriptional changes downstream of incretin stimulation. These assays help define agonist potency, signaling profile, receptor selectivity, and functional response compared with native GLP-1 or other GLP-1 analogs. In pancreatic β-cell research, AMG133 peptide payload TFA can support studies of insulinotropic signaling. GLP-1R activation enhances insulin secretion under elevated glucose conditions, making glucose-dependent assay design essential. Researchers may apply the peptide to β-cell lines, primary islets, stem-cell-derived β-like cells, or receptor-expressing model systems to measure insulin release, granule exocytosis, cAMP signaling, calcium dynamics, β-cell survival, and stress-response pathways. These workflows are useful for studying how GLP-1 analogs improve β-cell functional output in metabolic research models. Obesity and appetite-regulation research represent another important application. GLP-1R signaling influences feeding behavior through central nervous system pathways, vagal signaling, gastrointestinal motility, and endocrine communication. AMG133 peptide payload TFA may be used in receptor pharmacology and cellular pathway studies related to satiety signaling, neuroendocrine regulation, and energy-balance mechanisms. In experimental metabolic models, GLP-1 analog activity is often assessed through food intake, body weight, gastric emptying, and metabolic hormone readouts, although product content should remain focused on research use rather than clinical claims. AMG133 peptide payload TFA is also relevant to peptide payload and conjugate research. The peptide is described as a key payload component for synthesis of AMG 133-related constructs, supporting research into engineered peptide-based metabolic disease platforms. Payload design can influence receptor activity, pharmacokinetics, tissue exposure, conjugation compatibility, and biological durability. Researchers may study how the peptide behaves when incorporated into larger conjugates, antibody-peptide architectures, linker systems, or other delivery formats. Important parameters include peptide stability, receptor activation after conjugation, linker integrity, steric accessibility, and retention of GLP-1R agonist function. In metabolic disease research, GLP-1 analog peptides are commonly studied in models of insulin resistance, obesity, type 2 diabetes, hepatic steatosis, and impaired glucose tolerance. AMG133 peptide payload TFA can be used as a research tool to examine incretin-related mechanisms such as improved glucose-stimulated insulin secretion, reduced glucagon output, altered nutrient handling, and downstream metabolic signaling. It may also be compared with GIP, glucagon, oxyntomodulin, exendin-based analogs, and multi-agonist peptide systems to evaluate pathway-specific and combined metabolic effects. The peptide may also support drug-discovery assay development. GLP-1R agonist peptides are used to establish receptor assay windows, validate reporter cell lines, compare analog potency, and screen candidate constructs. AMG133 peptide payload TFA can serve as a reference payload in workflows evaluating receptor activation, peptide stability, conjugation chemistry, degradation resistance, and functional activity after structural modification. Analytical methods may include HPLC, LC-MS, peptide mapping, stability testing, and receptor-based bioassays. Because GLP-1 analog behavior can depend on peptide structure and formulation, experimental controls are important. Recommended controls include vehicle, native GLP-1, exendin-4 or another validated GLP-1R agonist, receptor-negative cells, GLP-1R antagonist blockade, receptor knockdown or knockout where available, dose-response analysis, time-course testing, peptide stability controls, and cell viability assays. For β-cell experiments, low- and high-glucose conditions should be included because GLP-1-mediated insulin secretion is glucose-dependent. Overall, AMG133 peptide payload TFA is a specialized GLP-1 analog peptide for metabolic and peptide-conjugate research. It supports GLP-1 receptor pharmacology, incretin signaling studies, β-cell insulin secretion assays, obesity-related pathway research, appetite-control models, metabolic disease mechanism studies, peptide payload development, AMG 133-related synthesis workflows, and next-generation peptide-based metabolic research platforms.

Reference: Veniant, M. M., Lu, S. C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., ... & Strande, J. L. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism, 6(2), 290-303.